Levetiracetam Viatris (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A in presynaptic neurons. This binding modulates neurotransmitter release, stabilizes neuronal firing, and reduces abnormal hyper‑synchronization, thereby lowering the likelihood of seizure generation.

The appropriate dose of Levetiracetam Viatris is determined by the prescribing clinician based on the patient’s age, weight, renal function, and clinical response. Healthcare professionals adjust the regimen to achieve optimal seizure control while monitoring safety.

Safety data for levetiracetam in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Levetiracetam offers a distinct mechanism (SV2A binding) and is generally well tolerated, with fewer drug‑enzyme interactions than many older antiepileptics such as carbamazepine or phenytoin. It can be used as monotherapy or adjunctive therapy, but choice of agent depends on seizure type, comorbidities, and individual patient response.

Levetiracetam Viatris should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain sterility and potency.

Levetiracetam Viatris is administered by intravenous injection or infusion under the supervision of qualified healthcare personnel. The exact rate and volume are determined by the prescriber, taking into account the patient’s clinical condition and any concurrent therapies.

Serious adverse events include severe allergic reactions (e.g., anaphylaxis, Stevens‑Johnson syndrome), blood dyscrasias such as neutropenia or thrombocytopenia, and significant mood changes including depression or suicidal ideation. Prompt medical evaluation is essential if any of these occur.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any component of the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those taking interacting anticonvulsants that markedly reduce its plasma levels.